Table 1 Differences in latency period in vivo between ASP13 and CYS12 transfectants
From: The impact of KRAS mutations on VEGF-A production and tumour vascular network
ASP13 | CYS12 | ||||||
|---|---|---|---|---|---|---|---|
Clone 4 (n = 10) | Clone 6 (n = 10) | Clone 2 (n = 10) | Clone 5 (n = 10) | Clone 4.3 (n = 10) | Clone 4.6 (n = 10) | ||
Days ± SD | 30,1 ± 6,5 | 24,5 ± 6,1 | 42 ± 0 | 9,7 ± 7,9 | 8.4 ± 0.9 | 13,2 ± 1,7 | |
Mean ± SD | 32.2 ± 8.9 | 10.4 ± 2.4 | P < 0.04 | ||||